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Abstract 
Hepatitis C Virus (HCV) is a major global disease which often leads to chronicity and is potential to liver failure. There is no 
anti-HCV vaccine and the high diversity of viral genotypes will probably make it very difficult to develop a vaccine. Therefore, 
the development of new drugs for HCV treatment is highly required. It is commonly known that numerous important modern 
drugs have been developed from molecules originally isolated from natural sources. In this study, we tested the leave extract and 
fractions of Ficus fistulosa for their anti-HCV activities by cell culture method using Huh7it cells and HCV JFH1a. The result 
showed that ethanol extract of Ficus fistulosa (FFL) inhibited HCV JFH1a with IC50 value of 20.43±4.51 μg/ml. Toxicity test 
also indicated that FFL was not toxic with CC50 value of >200 μg/ml. The extract was further fractionated using chloroform 
(FFLC) and butanol (FFLB) successively. FFLC showed anti-HCV activity with IC50 value of 5.67±1.54 μg/ml and CC50 value 
of >100 μg/ml (Selectivity index >17.65). Further separation of FFLC by open column chromatography resulted in 12 
subfractions (FFLC1-C12). Two subfractions, FFLC10, and FFLC11 showed high selectivity index (>100) with IC50 value of 
0.60±0.30 μg/ml and 0.43±0.29 μg/ml, respectively. Therefore the leave extract (FFL) and fractions (FFL10, FFL11) of Ficus 
fistulosa would be a good candidate to develop antiviral against HCV. 
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1. Introduction 
Hepatitis C was first identified in 1989 as a disease that infects the liver, which is commonly caused by a virus. 
An estimated 130 to 170 million people, 2% to 3% of the world’s population, are living with HCV infection and 
almost 350,000 people die of HCV each year. The prevalence of HCV in Indonesia is still more than 2 percent 
(based on serosurveys of voluntary blood donors). Three out of four people with Hepatitis C are potential to 
suffering from chronic hepatitis C and 10% up to 40% of people with untreated chronic hepatitis C will be likely to 
develop scarring of the liver (cirrhosis). Approximately 20% of people with cirrhosis will then develop liver failure, 
and 5% will develop liver cancer, both of which can be fatal1-4. 
HCV is a positive single stranded RNA virus of approximately 9,6 kB that encodes a long polyprotein precursor 
of ~3,000 amino acids, which is posttranslationally processed by host and virus proteases into mature proteins, 
including structural proteins (C, E1, E2, and p7) and nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B)5,6. The therapy using pegylated interferon alpha/ribavirin was only effective in approximately 80% and 40–
50% of patients infected with HCV genotypes 2–3 and 1, respectively7. It has severe side effects such as headache, 
pyrexia, myalgia, and rigors and high cost8-10. Thus, the development of safe and inexpensive antiviral drugs is 
highly required. 
More than 40% of all currently prescribed drugs is derived from chemicals that have been initially identified in 
plants. Many phytochemicals that have been identified display considerable inhibition of HCV at some stages of the 
life cycle11,12. Ficus fistulosa is locally known as Beunying and traditionally used to treat wounds. Ficus species are 
reported as anti Herpes Simplex Virus -1 and 2 (HSV-1, HSV-2), Varicella-Zoster Virus (VZV), Murine Sarcoma 
Virus (MuSV), anti Moloney Murine Leukemia Virus (MuLV)13, antimicrobes14, and antioxidant15. Our last 
publications also reported that Ficus fistulosa  extract had Anti-HCV activities against 9 different genotypes (1a to 
7a, 1b and 2b)16. The purpose of this study was to determine the active fractions of Ficus fistulosa againts HCV.  
2. Methods 
2.1. Cells and viruses 
Huh7it cells were cultivated in DMEM-Dulbeco’s Modiffied Eagle Medium (GIBCO Invitrogen)  supplementing 
10% Fetal Bovine Serum (FBS, GIBCO-Invitrogen), 1x Non-Essential Amino Acids (NEAA, GIBCO-Invitrogen), 
and 0.15 mg/ml Kanamycin solution (SIGMA) in 5% CO2 at 37°C. The culture condition of Huh7it cells was 
observed under a microscope every day. JFH1a virus (50μl) was propagated by using Huh7it cells. It was suspended 
in 4 ml medium containing Huh7it (1.8x107 cells) and incubated at 37°C in 5% CO2 for 4 hr with agitation for every 
30 min. The infected cells were divided into eight T-75 flasks by supplying 10 ml culture medium per flask and 
incubated for 3 days. We harvested supernatant and removed cell debris by centrifugation at 1,500 rpm, 10 min, 
4°C. The supernatant was concentrated by using Amicon-Ultra-15 centrifuge filter. Concentrated supernatant was 
aliquoted and stored at -80°C until use. 
2.2. Extraction and fractionation of Ficus fistulosa 
 
 
 
Fig. 1. Extraction and fractionation of Ficus fistulosa 
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Ficus fistulosa was extracted by ultrasonic assisted extraction method using ethanol 80% as a solvent. F.fistulosa 
extract (FFL) was then fractionated using chloroform and butanol successively to obtain chloroform fraction (FFLC) 
and butanol fraction (FFLB). FFLC was separated further by open column chromatography using sephadex LH-20 
as a stationary phase and methanol-chloroform (95%:5%) as a mobile phase that resulted in 12 subfractions 
(FFLC1-C12).  
2.3. Analysis of anti-HCV activities  
Huh7it cells were seeded in 48-well plates (5 × 104  cells/well) and virus JFH1a with moi 0.1. A U-type 96 well 
plate was used to make dilution series of two-times higher than concentration used in an anti-HCV assay. JFH1a 
was mixed with the serial dilutions first and inoculated to the cells. After 2 hours, the cells were washed with a 
medium and incubated in the medium containing extracts for 46 hours to determine IC50. 
 
2.4. Virus titration and Immunostaining 
The virus supernatant was dilluted serially 30-fold in a complete DMEM, inoculated onto Huh7it cells seeded on 
96 well plate, incubated for 4 hrs, and replaced with MC-DMEM 0.4%. At 41 hr of post infection, cells were fixed 
by using 3.7% Formaldehyde for 15 min, permeabilized with 0.5% triton X-100 in PBS for 10 min, washed with 
PBS three times 200 μl/well, added with HCV-infected patient’s serum for 60 min, followed by incubation with 
HRP-Goat anti human Ig antibody diluted with 2% BSA/PBS (x250) (50 μl/well) room temperature for 60 min, 
added with staining solution (DAB Thermo Scientific, USA), and incubated for 10-15 min at a room temperature 
until visualizing brown color. Consequently, the reaction was stopped by adding dH2O. 
 
2.5. Cytotoxicity assay 
The cytotoxicity of the samples was assessed by MTT assay. Huh7it cells in 96 well plates were treated with 
serial dillutions of the samples or the control. The condition of the cells was observed after 46 hr incubation, and the 
toxicity was checked under a microscope. The medium was removed from 96 well plates, added with MTT 10% 150 
μl/well by a multichannel pipette, and incubated for 4 hr at 37°C. MTT solution was removed from 96 well plates 
and 100 ȝl/well DMSO 100% was added to dissolve. The absorbance was checked at 560 nm and 750 nm and 
shaken 0.5 min before the absorbance was read. 
3. Results and discussion 
Table 1. Antiviral activity (IC50) against JFH1a, cytotoxicity (CC50) and selectivity index (SI) of  Ficus fistulosa. 
Samples Ficus fistulosa IC50 
(μg/ml) 
CC50 
(μg/ml) 
SI 
(Selectivity Index) 
Ethanol extract (FFL)  20.43 ± 4.51 >200 >9.79 
Buthanol fraction (FFLB)  74.10 ± 18.24 >1000 >13.50 
Cloroform fraction (FFLC)  5.67 ± 1.54 >100 >17.65 
Cloroform subfraction 1 (FFLC1)  78.70 ± 0.99 >500 >6.35 
Cloroform subfraction 2 (FFLC2)  26.73 ± 5.61 >200 >7.48 
Cloroform subfraction 3 (FFLC3)  34.78 ± 3.85 >200 >5.75 
Cloroform subfraction 4 (FFLC4)  24.65 ± 5.31 >50 >2.03 
Cloroform subfraction 5 (FFLC5)  34.43 ± 1.17 >100 >2.90 
Cloroform subfraction 6 (FFLC6)  21.56 ± 8.69 >50 >2.32 
Cloroform subfraction 7 (FFLC7)  11.32 ± 3.88 >50 >4.42 
Cloroform subfraction 8 (FFLC8)  5.57 ± 2.80 >50 >8.98 
Cloroform subfraction 9 (FFLC9)  1.50 ± 0.57 >50 >33.33 
Cloroform subfraction 10 (FFLC10)  0.60 ± 0.30 >100 >166.67 
Cloroform subfraction 11 (FFLC11)  0.43 ± 0.29 >50 >115.38 
Cloroform subfraction 12 (FFLC12)  8.55 ± 6.58 >500 >58.48 
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In this study, we tested the extract of Ficus fistulosa (FFL) and the subfractions for their anti-HCV activities by 
cell culture method using Huh7it cells and HCV JFH1a. The result showed that FFL inhibited HCV JFH1a with IC50 
value of 20.43±4.51 μg/ml. Toxicity test also indicated that FFL was not toxic with CC50 value of >200 μg/ml 
(Table 1). These results were similar with the previous report which suggested FFL as a good candidate for antiviral 
against HCV. The previous study reported that F.fistulosa leave extract was showed antiviral activity against HCV 
J6/JFH1-P47 strain and -P1 strains with IC50 value of 15.0 and 5.7 ȝg/ml, respectively. Time of addition experiment 
revealed that FFL inhibited at the entry step. Further analysis was needed to determine the possible anti-HCV 
compound contained in the extract16.  
Regarding to the data obtained from the study, the separation of FFL was performed. FFL was fractionated 
further by using chloroform and butanol successively to obtain chloroform fraction (FFLC) and butanol fraction 
(FFLB). Bioassay-guided fractionation was taken in this study. The results showed that FFLC possessed anti-HCV 
activity with IC50 value of 5.67±1.54 μg/ml and CC50 value of >100 μg/ml (SI >17.65). On the other hand, FFLB 
showed weaker inhibitory activity with IC50 value of  74.10±18.24 μg/ml and CC50 value of >1000 μg/ml. FFLC as 
an active fraction was separated further to get closer to the anti-HCV compound determination. The separation of 
FFLC was conducted by open column chromatography using sephadex LH-20 as a stationary phase and methanol-
chloroform (95%-5%) as a mobile phase resulted in 12 subfractions (FFLC1-C12). Anti-HCV activity test was 
conducted to identify the inhibitory activity of subfractions. The results showed that five of twelve subfractions have 
IC50 value of 0.43-8.55 μg/ml. Meanwhile, the other subfractions have IC50 value of 11.32-78.70 μg/ml.  The most 
potential inhibitory activity was showed by FFLC10 and FFLC11 with high selectivity index >166.67 and >115.38, 
respectively. Dose dependent inhibition showed that FFLC10 and FFLC11 exhibited JFH1a 100 % with 
concentration value < 2 μg/ml (Fig. 2). 
 
 
 
 
Fig. 2. Dose-dependent inhibition of JFH1a infection by (a) FFLC10 of Ficus fistulosa; (b) FFLC11 of Ficus fistulosa. 
 
Identification of five active subfractions by Thin Layer Chromatography (TLC) revealed that subfractions 
contained flavonoids, terpenoids and chlorophyll compounds (Fig. 3). Chlorophyll compounds were shown by the 
presence of green spots after TLC plate was spayed using H2SO4 10% and heated 105oC for 5 minutes (Fig. 3c) and 
by the red spots under uv 365 nm after sprayed and heated (Fig. 3d). FFLC8 until FFLC12 which contained green 
and red spots had IC50 less than 10 μg/ml. The presence of chlorophyll compounds was possible to increase the 
antiviral activity of subfractions. The previous study reported that chlorophyll catabolites, pheophorbide a and 
pyropheophorbide a, isolated from Morinda citrifolia, showed potent anti-HCV activities with IC50 of 0.3 and 0.2 
μg/ml, respectively17. An alkylated porphyrin, chlorophyllide, also reported that directly and quantitatively disrupted 
Hepatitis B virus (HBV) virions, without detectably affecting cell viability or intracellular viral gene products18. 
These reports supported our suggestion about the chlorophyll compounds activity. Therefore, FFLC10 and 
FFLC11would become a good target for futher purification.  
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Fig 3. Thin Layer Chromatography (TLC) profile of sub fractions C12F C1-12 using silica gel F254 as stationary phase and chloroform:methanol 
95:5 v/v as development solvent; observed under (a) uv 254 nm; (b) uv 365 nm; (c) using spray reagent H2SO4 10% and heated 105oC for 5 
minutes; (d) observed under uv 365 nm after using spray reagent and heated. 
 
4. Conclusions 
The extract FFL, chloroform fraction FFLC, and subfractions FFLC10 and FFLC11 of Ficus fistulosa have a 
consistency of antiviral activities and would be a good candidate for the development of an antivirus against HCV.  
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